Abbott Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abbott Laboratories (ABT).

Price Target Range — 8 Quarters

Analyst Consensus — 24 Analysts

22Buy

2Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$127Upside to Avg. PT+23.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Argus Research	David Round	Downgrade	Buy→Hold	—
Oct 23, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$119→$120
Oct 22, 2026	Citigroup	Joanne Wuensch	PT Cut	Buy	$125→$122
Oct 22, 2026	RBC Capital	Kendall Au	PT Cut	Outperform	$130→$125
Oct 22, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$112→$119
Oct 22, 2026	JP Morgan	Robbie Marcus	PT Cut	Overweight	$120→$118
Oct 22, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$135→$118
Oct 22, 2026	Baird	David Rescott	PT Raise	Outperform	$121→$123
Oct 22, 2026	BTIG	Marie Thibault	PT Cut	Buy	$134→$125
Oct 16, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$135
Oct 7, 2026	Barclays	Matt Miksic	Initiate	Overweight	$120
Oct 2, 2026	Rothschild & Co	Ed Ridley-Day	Upgrade	Neutral→Buy	$119→$127
Sep 8, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$135
Aug 21, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$115→$135
Aug 14, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$112→$125
Aug 13, 2026	Wolfe Research	Mike Polark	Upgrade	Peer Perform→Outperform	$130
Jul 28, 2026	UBS	Patrick Wood	PT Cut	Buy	$135→$125
Jul 17, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$108→$112
Jul 17, 2026	Piper Sandler	Adam Maeder	PT Raise	Overweight	$115→$118
Jul 17, 2026	JP Morgan	Robbie Marcus	PT Raise	Overweight	$110→$120

Analyst Ratings News

This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.

Avi Kapoor

PRO
Argus Research Downgrades Abbott Laboratories to Hold

Argus Research analyst David Round downgrades Abbott Laboratories (NYSE:ABT) from Buy to Hold.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.

Benzinga Newsdesk

Abbott Laboratories

뉴스

파트너 / 기고자

벤징가 글로벌

Abbott Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PRO
Argus Research Downgrades Abbott Laboratories to Hold

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

PRO
Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

PRO
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119

People Also Watch

People Also Watch

Abbott Laboratories

뉴스

파트너 / 기고자

벤징가 글로벌

Abbott Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

PROArgus Research Downgrades Abbott Laboratories to Hold

PROWells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

PROCitigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

PRORBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

PROWells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119

People Also Watch

People Also Watch

PRO
Argus Research Downgrades Abbott Laboratories to Hold

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

PRO
Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

PRO
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119